AllAnalyst Report
Morningstar•May 25, 2023
Morningstar•May 25, 2023Eli Lilly and Company: Novo Nordisk and Eli Lilly Lead Potential $60 Billion Obesity Drug Market; Valuations Look Rich
Summary
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Jardiance, Trulicity, Humalog, an
Subscribe to Yahoo Finance Plus Essential for full access
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Actions
Download Full ReportRelated Reports
- Daily Spotlight: Demand Shifts for U.S. DebtApr 19, 2024 •
BIIB
- Analyst Report: UnitedHealth Group IncorporatedApr 18, 2024 •
UNH
- Analyst Report: Johnson & JohnsonApr 18, 2024 •
JNJ
- Market Update: DFS, JNJ, LVS, TRVApr 18, 2024 •
DFS, JNJ, LVS, TRV
- Analyst Report: AbbVie IncApr 18, 2024 •
ABBV
Analyst Profile
Damien Conover
Sector DirectorDamien Conover, CFA, is director of healthcare equity research for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He is also director of equity strategy, responsible for helping to shape, package, and surface research based on Morningstar's investment philosophy by working closely with the firm's North American sector strategists and directors.Before joining Morningstar in 2007, Conover was an equity research analyst covering the healthcare sector for Raymond James, Bank of Montreal, and Tucker Anthony.Conover holds bachelor's and master's degrees in finance from the University of Wisconsin and was a member of its Applied Security Analysis Program. He also holds the Chartered Financial Analyst® designation.